What's Happening?
Delcath Systems has announced that the CHOPIN Phase 2 clinical trial met its primary endpoint, demonstrating the efficacy of combining CHEMOSAT Hepatic Delivery System with immune checkpoint inhibitors
ipilimumab and nivolumab in treating metastatic uveal melanoma. The trial showed significant improvements in progression-free survival and overall survival compared to PHP treatment alone. The combination group achieved a one-year progression-free survival rate of 54.7% versus 15.8% in the PHP group. The trial results were presented at the European Society of Medical Oncology Congress 2025.
Why It's Important?
Liver metastases are challenging to treat and often result in poorer outcomes for cancer patients. The CHOPIN trial results suggest that combining PHP with immune checkpoint inhibitors could enhance treatment efficacy, offering new hope for patients with liver-dominant diseases. This approach could lead to improved survival rates and quality of life for patients, potentially transforming the treatment landscape for liver cancers.
What's Next?
The trial results support further investigation into the combination of PHP and immune checkpoint inhibitors for other cancers with liver-dominant disease. Delcath Systems plans to explore this potential in future studies, aiming to expand the application of this treatment approach. Regulatory processes will be crucial to making these therapies widely available, and the oncology community will be closely monitoring these developments.
Beyond the Headlines
The CHOPIN trial highlights the potential synergy between PHP and immune checkpoint inhibitors, offering insights into the liver's immunosuppressive nature. Understanding these mechanisms could lead to breakthroughs in treating liver metastases across various cancer types, emphasizing the importance of continued research in this area.
